Access to the waiting list and to kidney transplantation for people living with HIV: A national registry study.
Access to Information
Adult
Cohort Studies
Female
Follow-Up Studies
HIV
/ isolation & purification
HIV Infections
/ complications
Health Services Accessibility
/ standards
Healthcare Disparities
/ standards
Humans
Kidney Failure, Chronic
/ surgery
Kidney Transplantation
/ statistics & numerical data
Male
Middle Aged
Prognosis
Registries
Renal Dialysis
Survival Rate
Waiting Lists
/ mortality
HIV infection
clinical research/practice
end-stage renal disease
infection and infectious agents - viral: human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS)
infectious disease
kidney transplantation
kidney transplantation/nephrology
organ allocation
organ procurement and allocation
panel reactive antibody (PRA)
renal replacement therapy
waiting list
Journal
American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons
ISSN: 1600-6143
Titre abrégé: Am J Transplant
Pays: United States
ID NLM: 100968638
Informations de publication
Date de publication:
12 2019
12 2019
Historique:
received:
03
01
2019
revised:
27
05
2019
accepted:
03
06
2019
pubmed:
18
6
2019
medline:
18
9
2020
entrez:
18
6
2019
Statut:
ppublish
Résumé
We compared access to a kidney transplantation (KT) waiting list (WL) and to KT between people living with HIV (PLHIV) and HIV-uninfected controls. Using the REIN (the national Renal Epidemiology and Information Network registry), we included all PLHIV initiating dialysis in France throughout 2006-2010 and HIV-uninfected controls matched for age, sex, year of dialysis initiation, and the existence of a diabetic nephropathy. Patients were prospectively followed until December 2015. We used a competitive risk approach to assess the cumulative incidence of enrollment on WL and of KT, with death as a competing event (subdistribution hazard ratio adjusted on comorbidities, asdHR). There were 255 PLHIV in the REIN (median age 47 years) of whom 180 (71%) were also found in the French Hospital Database on HIV (FHDH-ANRS CO4) including 126 (70%) known to be on antiretroviral therapy with HIV viral suppression (VS). Five years after dialysis initiation, 65%, and 76%, of treated PLHIV with VS, and of HIV-uninfected controls were enrolled on a WL (asdHR 0.68; 95% CI 0.50-0.91). Access to KT was also less frequent and delayed for treated PLHIV with VS (asdHR 0.75, 95% CI, 0.52-1.10). PLHIV continue to face difficulties to access KT.
Identifiants
pubmed: 31206243
doi: 10.1111/ajt.15500
pii: S1600-6135(22)09334-0
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
3345-3355Subventions
Organisme : Agence de la biomedicine, France
Pays : International
Informations de copyright
© 2019 The American Society of Transplantation and the American Society of Transplant Surgeons.
Références
Mocroft A, Kirk O, Gatell J, et al. Chronic renal failure among HIV-1-infected patients. AIDS. 2007;21(9):1119-1127.
Ryom L, Mocroft A, Kirk O, et al. Predictors of advanced chronic kidney disease and end-stage renal disease in HIV-positive persons. AIDS. 2014;28(2):187-199.
Morlat P, Vivot A, Vandenhende MA, et al. Role of traditional risk factors and antiretroviral drugs in the incidence of chronic kidney disease, ANRS CO3 Aquitaine cohort, France, 2004-2012. PLoS ONE. 2013;8(6):e66223.
Hallan SI, Coresh J, Astor BC, et al. International comparison of the relationship of chronic kidney disease prevalence and ESRD risk. J Am Soc Nephrol. 2006;17(8):2275-2284.
Cohen SD, Kopp JB, Kimmel PL. Kidney diseases associated with human immunodeficiency virus infection. N Engl J Med. 2017;377(24):2363-2374.
Locke JE, Gustafson S, Mehta S, et al. Survival benefit of kidney transplantation in HIV-infected patients. Ann Surg. 2016;265(3):604-608.
Stock PG, Barin B, Murphy B, et al. Outcomes of kidney transplantation in HIV-infected recipients. N Engl J Med. 2010;363(21):2004-2014.
Kucirka LM, Durand CM, Bae S, et al. Induction immunosuppression and clinical outcomes in kidney transplant recipients infected with human immunodeficiency virus. Am J Transplant. 2016;16(8):2368-2376.
Harbell J, Fung J, Nissen N, et al. Surgical complications in 275 HIV-infected liver and/or kidney transplantation recipients. Surgery. 2012;152(3):376-381.
Locke JE, James NT, Mannon RB, et al. Immunosuppression regimen and the risk of acute rejection in HIV-infected kidney transplant recipients. Transplantation. 2014;97(4):446-450.
Locke JE, Montgomery RA, Warren DS, Subramanian A, Segev DL. Renal transplant in HIV-positive patients: long-term outcomes and risk factors for graft loss. Arch Surg. 2009;144(1):83-86.
Touzot M, Pillebout E, Matignon M, et al. Renal transplantation in HIV-infected patients: the Paris experience. Am J Transplant. 2010;10(10):2263-2269.
Kumar MS, Sierka DR, Damask AM, et al. Safety and success of kidney transplantation and concomitant immunosuppression in HIV-positive patients. Kidney Int. 2005;67(4):1622-1629.
Stock PG, Roland ME, Carlson L, et al. Kidney and liver transplantation in human immunodeficiency virus-infected patients: a pilot safety and efficacy study. Transplantation. 2003;76(2):370-375.
Roland ME, Barin B, Carlson L, et al. HIV-infected liver and kidney transplant recipients: 1- and 3-year outcomes. Am J Transplant. 2008;8(2):355-365.
Gruber SA, Doshi MD, Cincotta E, et al. Preliminary experience with renal transplantation in HIV+ recipients: low acute rejection and infection rates. Transplantation. 2008;86(2):269-274.
Mazuecos A, Rodriguez Benot A, Moreno A, et al. Renal replacement therapy in patients with HIV infection in a European region: outcomes following renal transplantation. Transplant Proc. 2012;44(7):2053-2056.
Roland ME, Barin B, Huprikar S, et al. Survival in HIV-positive transplant recipients compared with transplant candidates and with HIV-negative controls. AIDS. 2016;30(3):435-444.
Locke JE, Mehta S, Reed RD, et al. A national study of outcomes among HIV-infected kidney transplant recipients. J Am Soc Nephrol. 2015;26(9):2222-2229.
Stock PG. Strengths and weaknesses of using SRTR data to shape the management of the HIV-infected kidney transplant recipient. Am J Transplant. 2017;17(12):3001-3002.
Trullas JC, Cofan F, Tuset M, et al. Renal transplantation in HIV-infected patients: 2010 update. Kidney Int. 2011;79(8):825-842.
Ailioaie O, Arzouk N, Valantin MA, et al. Infectious complications in HIV-infected kidney transplant recipients. Int J STD AIDS. 2018;29(4):341-349.
Sawinski D, Bloom RD. Current status of kidney transplantation in HIV-infected patients. Curr Opin Nephrol Hypertens. 2014;23(6):619-624.
Frassetto L, Floren L, Barin B, et al. Changes in clearance, volume and bioavailability of immunosuppressants when given with HAART in HIV-1 infected liver and kidney transplant recipients. Biopharm Drug Dispos. 2013;34(8):442-451.
van Maarseveen EM, Rogers CC, Trofe-Clark J, van Zuilen AD, Mudrikova T. Drug-drug interactions between antiretroviral and immunosuppressive agents in HIV-infected patients after solid organ transplantation: a review. AIDS Patient Care STDS. 2012;26(10):568-581.
Locke JE, Mehta S, Sawinski D, et al. Access to kidney transplantation among HIV-infected waitlist candidates. Clin J Am Soc Nephrol. 2017;12(3):467-475.
Couchoud C, Stengel B, Landais P, et al. The renal epidemiology and information network (REIN): a new registry for end-stage renal disease in France. Nephrol Dial Transplant. 2006;21(2):411-418.
Mary-Krause M, Grabar S, Lievre L, et al. Cohort profile: French hospital database on HIV (FHDH-ANRS CO4). Int J Epidemiol. 2014;43(5):1425-1436.
Cecka JM, Calculated PRA. (CPRA): the new measure of sensitization for transplant candidates. Am J Transplant. 2010;10(1):26-29.
O'Grady J, Taylor C, Brook G. Guidelines for liver transplantation in patients with HIV infection (2005). HIV Med. 2005;6(Suppl 2):149-153.
Sawinski D, Wyatt CM, Casagrande L, et al. Factors associated with failure to list HIV-positive kidney transplant candidates. Am J Transplant. 2009;9(6):1467-1471.
Lee DH, Boyle SM, Malat GE, et al. Barriers to listing for HIV-infected patients being evaluated for kidney transplantation. Transpl Infect Dis. 2017;19(6):e12777. https://doi.org/10.1111/tid.12777.
Roth D, Nelson DR, Bruchfeld A, et al. Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study. Lancet. 2015;386(10003):1537-1545.
Tricot L, Teicher E, Peytavin G, et al. Safety and efficacy of raltegravir in HIV-infected transplant patients cotreated with immunosuppressive drugs. Am J Transplant. 2009;9(8):1946-1952.
Waki K, Sugawara Y. Implications of integrase inhibitors for HIV-infected transplantation recipients: raltegravir and dolutegravir (S/GSK 1349572). Biosci Trends. 2011;5(5):189-191.
Matignon M, Lelièvre JD, Lahiani A, et al. Low incidence of acute rejection within 6 months of kidney transplantation in HIV-infected recipients treated with raltegravir: the Agence Nationale de Recherche sur le Sida et les Hépatites Virales (ANRS) 153 TREVE trial. HIV Med. 2019;20(3):202-213.
Gupta SK, Eustace JA, Winston JA, et al. Guidelines for the management of chronic kidney disease in HIV-infected patients: recommendations of the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis. 2005;40(11):1559-1585.
Lassalle M, Monnet E, Ayav C, et al. The Renal Epidemiology and Information Network (REIN) Registry Annual Report 2017: a summary [published online ahead of print May 30, 2019]. Transpl Int. https://doi.org/10.1111/tri.13466.
USRDS. Transplantation. https://www.usrds.org/2017/view/v2_06.aspx. Accessed February 19, 2019.
Harris RJ, Sterne JA, Abgrall S, et al. Prognostic importance of anaemia in HIV type-1-infected patients starting antiretroviral therapy: collaborative analysis of prospective cohort studies. Antivir Ther. 2008;13(8):959-967.
Dezube BJ, Aboulafia DM, Pantanowitz L. Plasma cell disorders in HIV-infected patients: from benign gammopathy to multiple myeloma. AIDS Read. 2004;14(7):372-374, 377-379.
Cohen JB, Locke JE, Shelton B, et al. Disparity in access to kidney allograft offers among transplant candidates with human immunodeficiency virus. Clin Transplant. 2019;33(2):e13466.
Agence de la Biomédecine. Le programme R.E.I.N. https://www.agence-biomedecine.fr/Le-programme-REIN. Accessed January 3, 2019.
INSERM. ANRS - France REcherche Nord&Sud Sida-hiv Hépatites. http://www.anrs.fr. Accessed March 1, 2019.
Classification and diagnosis of diabetes: standards of medical care in diabetes-2018. Diabetes Care. 2018;41(suppl 1):S13-S27.